Supriya Lifescience Limited

NSE: SUPRIYA BSE: SUPRIYA

NSE

614.35 24.60 (4.17%)

Prev Close

589.75

Open Price

567.05

Volume

251,518

Today Low / High

567.05 / 620.25

52 WK Low / High

305.5 / 835.2

Range

584 - 645

BSE

613.70 25.45 (4.33%)

Prev Close

588.25

Open Price

562.2

Volume

13,999

Today Low / High

562.2 / 623.8

52 WK Low / High

304.05 / 835.35

Range

583 - 644

The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 614.35 (target range: 584 - 645), reflecting a change of 24.6 (4.17126%). On the BSE, it is listed at 613.7 (target range: 583 - 644), showing a change of 25.45 (4.32639%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.

04 Mar 567.05 8.31%

03 Mar 592.00 -0.38%

28 Feb 619.95 -3.64%

27 Feb 638.25 -1.81%

25 Feb 648.00 -1.50%

24 Feb 639.85 1.48%

21 Feb 675.45 -5.27%

20 Feb 637.00 6.58%

19 Feb 627.00 1.23%

18 Feb 649.95 -3.43%

17 Feb 651.00 -1.17%

14 Feb 698.40 -4.53%

13 Feb 717.00 -3.72%

12 Feb 671.80 6.70%

11 Feb 724.80 -5.91%

10 Feb 781.00 -7.36%

07 Feb 751.00 3.01%

06 Feb 769.75 -2.19%

05 Feb 755.00 1.95%

04 Feb 707.25 7.92%

Supriya Lifescience Limited Graph

If you are looking Target Price for Supriya Lifescience Limited T1, T2, T3, for both Bullish or Bearish. For Bullish T1, T2, T3 and for Bearish T1, T2, T3. The stock current price is 614, with potential price targets ranging from T1, T2, T3 in both directions based on market conditions.

Scenario	Price	Target	Range
Bullish Scenario	613.70	619.84	557.85 - 681.82
		625.97	500.78 - 751.17
		632.11	442.48 - 821.74
Bearish Scenario	613.70	607.56	546.81 - 668.32
		601.43	481.14 - 721.71
		595.29	416.70 - 773.88

ISIN

INE07RO01027

Industry

Biotechnology

Vol.Avg

302,031

Market Cap

49,468,753,020

Last Dividend

0.8

Official Website

Visit Website

IPO Date

2021-12-28

DCF Diff

213.50

DCF

376

Financial Ratios Every Investor Needs

Stock Dividend of SUPRIYA

Date	Label	Adj Dividend	Dividend	Record Date	Payment Date
2024-09-20	September 20, 24	0.8	0.8	2024-09-20	2024-10-27
2023-09-15	September 15, 23	0.6	0.6	2023-09-15	2023-10-29
2022-09-01	September 01, 22	0.6	0.6	2022-09-02	2022-10-16

Stock Rating Details for SUPRIYA

Metric	Value	Recommendation
Overall Rating	C-	Strong Sell
DCF Score	3	Neutral
ROE Score	1	Strong Sell
ROA Score	1	Strong Sell
Debt-to-Equity (DE) Score	1	Strong Sell
Price-to-Earnings (PE) Score	1	Strong Sell
Price-to-Book (PB) Score	1	Strong Sell

Annual Financial Income Report

Date	Revenue	Co.Rev	GP	GPR	R&D Expenses	G&A Expenses	Operating Income	Net Income	EPS	EBITDA	NIR
2024-03-31	570.37 Cr	359.55 Cr	210.82 Cr	0.3696	1.09 Cr	23.19 Cr	157.17 Cr	119.11 Cr	14.80	183.58 Cr	0.2088
2023-03-31	460.94 Cr	180.81 Cr	280.13 Cr	0.6077	1.24 Cr	19.23 Cr	117.17 Cr	89.86 Cr	11.16	138.39 Cr	0.1949
2022-03-31	519.37 Cr	229.89 Cr	289.49 Cr	0.5574	1.66 Cr	13.73 Cr	204.34 Cr	151.81 Cr	18.86	221.56 Cr	0.2923
2021-03-31	385.37 Cr	151.17 Cr	234.20 Cr	0.6077	0.66 Cr	10.52 Cr	166.39 Cr	123.59 Cr	16.89	178.15 Cr	0.3207
2020-03-31	311.65 Cr	162.75 Cr	148.90 Cr	0.4778	1.06 Cr	10.48 Cr	100.81 Cr	73.40 Cr	10.03	108.96 Cr	0.2355

Annual Financials Balance Sheet

Date	C&C Equ.	Tot. Assets	Tot. Liab.	Stock. Equity	Tot. Debt	Net Debt	Inv.	PP&E (Net)	Curr. Def. Rev.	Non-Curr. Def. Rev.	LT Invest.	Curr. Liab.
2024-03-31	68.17 Cr	921.24 Cr	105.87 Cr	815.3660 Cr	5.49 Cr	-62.68 Cr	85.25 Cr	457.30 Cr	14.87 Cr	0.00 Cr	63.80 Cr	76.8940 Cr
2023-03-31	85.25 Cr	820.28 Cr	120.82 Cr	699.4590 Cr	22.47 Cr	-62.78 Cr	115.77 Cr	328.06 Cr	1.66 Cr	0.00 Cr	25.30 Cr	95.7800 Cr
2022-03-31	165.78 Cr	734.76 Cr	119.08 Cr	615.6880 Cr	27.42 Cr	-138.36 Cr	92.31 Cr	231.67 Cr	25.45 Cr	2.93 Cr	0.05 Cr	99.6990 Cr
2021-03-31	31.07 Cr	445.82 Cr	176.88 Cr	268.9420 Cr	72.19 Cr	41.12 Cr	72.48 Cr	175.92 Cr	17.60 Cr	20.79 Cr	0.05 Cr	146.0190 Cr
2020-03-31	1.54 Cr	336.43 Cr	187.24 Cr	149.1930 Cr	84.52 Cr	82.98 Cr	49.46 Cr	135.01 Cr	22.91 Cr	3.68 Cr	0.05 Cr	155.3880 Cr

Annual Financials Cash Flow Statement

Date	Operating Cash	Investing Cash	Financing Cash	Free Cash	Cash Change	Cash at End	CapEx	Income	Debt Repay	Dividends	Inventory
2024-03-31	113.3070 Cr	-173.5750 Cr	-22.3590 Cr	-32.3480 Cr	-82.6260 Cr	74.9560 Cr	-145.6550 Cr	119.1140 Cr	-16.6250 Cr	-4.8290 Cr	30.5210 Cr
2023-03-31	66.1870 Cr	-133.1450 Cr	-3.3680 Cr	-42.2130 Cr	-70.3260 Cr	157.5820 Cr	-108.4000 Cr	123.4870 Cr	-4.6700 Cr	-4.8290 Cr	-23.4580 Cr
2022-03-31	48.8010 Cr	-59.8220 Cr	149.6520 Cr	-11.1030 Cr	138.6310 Cr	227.9080 Cr	-59.9040 Cr	207.2450 Cr	-0.7630 Cr	-4.3910 Cr	-19.8320 Cr
2021-03-31	79.9300 Cr	-47.4100 Cr	-14.9310 Cr	31.6890 Cr	17.5880 Cr	92.2930 Cr	-48.2410 Cr	167.3930 Cr	-11.6660 Cr	-3.9560 Cr	-23.0220 Cr
2020-03-31	116.0620 Cr	-24.5250 Cr	-29.2300 Cr	91.5370 Cr	62.3070 Cr	74.7050 Cr	-24.5250 Cr	96.2270 Cr	-7.6280 Cr	-17.6460 Cr	-18.7260 Cr

Quarterly Financial Income Report

Date	Revenue	Co.Rev	GP	GPR	Operating Income	Net Income	EPS	EBITDA	NIR
2024-12-31	185.65 Cr	61.78 Cr	123.87 Cr	0.6672	0.00 Cr	46.78 Cr	5.82	68.05 Cr	0.2520
2024-09-30	166.10 Cr	70.40 Cr	95.70 Cr	0.5761	59.97 Cr	46.15 Cr	5.71	67.24 Cr	0.2778
2024-06-30	160.63 Cr	73.34 Cr	87.29 Cr	0.5434	57.89 Cr	44.64 Cr	5.55	64.77 Cr	0.2779
2024-03-31	158.18 Cr	79.32 Cr	78.86 Cr	0.4986	51.59 Cr	36.93 Cr	4.59	57.69 Cr	0.2335
2023-12-31	140.07 Cr	54.62 Cr	85.45 Cr	0.6101	40.59 Cr	29.79 Cr	3.70	44.55 Cr	0.2127

Quarterly Financials Balance Sheet

Date	Cash & Equiv.	Short-Term Inv.	Cash & Short-Term	Net Receivables	Inventory	Total Curr. Assets	PP&E (Net)	Total Assets	Total Liabilities
2024-09-30	77.51 Cr	9.46 Cr	86.96 Cr	105.73 Cr	107.99 Cr	413.36 Cr	522.68 Cr	1,012.39 Cr	106.50 Cr
2024-06-30	0.00 Cr	0.00 Cr	74.96 Cr	0.00 Cr	0.00 Cr	74.96 Cr	0.00 Cr	0.00 Cr	-815.37 Cr
2024-03-31	74.96 Cr	11.12 Cr	74.96 Cr	111.68 Cr	85.25 Cr	397.80 Cr	457.30 Cr	921.24 Cr	105.87 Cr
2023-12-31	-115.81 Cr	231.62 Cr	115.81 Cr	0.00 Cr	0.00 Cr	115.81 Cr	0.00 Cr	0.00 Cr	0.00 Cr
2023-09-30	104.04 Cr	16.25 Cr	120.29 Cr	84.84 Cr	98.83 Cr	410.86 Cr	373.01 Cr	843.03 Cr	89.86 Cr

Quarterly Financials Cash Flow Statement

Date	Net Income	Operating Cash Flow	Net Cash Change	Cash at End	Cash at Beginning	Free Cash Flow
2024-06-30	44.64 Cr	0.00 Cr	0.00 Cr	0.00 Cr	0.00 Cr	0.00 Cr
2024-03-31	36.93 Cr	0.00 Cr	0.00 Cr	0.00 Cr	0.00 Cr	0.00 Cr
2023-12-31	29.79 Cr	7.92 Cr	7.92 Cr	111.96 Cr	104.04 Cr	7.92 Cr
2023-09-30	23.88 Cr	7.96 Cr	7.96 Cr	104.04 Cr	96.08 Cr	7.96 Cr
2023-06-30	28.51 Cr	7.91 Cr	7.91 Cr	85.28 Cr	77.37 Cr	7.91 Cr

Splits History

Date	Label	Split Ratio
No split history data available.

Similar Stocks: Biotechnology

Company Name	Symbol	Price	Market Cap	Volume
Biocon Limited	BIOCON	₹312.70	₹375,427,620,000.00	₹2,300,037.00
Syngene International Limited	SYNGENE	₹650.95	₹261,221,875,588.00	₹204,805.00
Piramal Pharma Limited	PPLPHARMA	₹192.36	₹255,020,923,752.00	₹2,871,342.00
Concord Biotech Limited	CONCORDBIO	₹1,650.50	₹172,669,038,100.00	₹269,838.00
Blue Jet Healthcare Limited	BLUEJET	₹787.75	₹136,647,384,605.00	₹404,019.00
Jubilant Ingrevia Limited	JUBLINGREA	₹601.25	₹95,767,701,250.00	₹363,012.00
Supriya Lifescience Limited	SUPRIYA	₹614.30	₹49,440,584,040.00	₹251,433.00
Dishman Carbogen Amcis Limited	DCAL	₹204.58	₹32,074,666,140.00	₹210,341.00
Zota Health Care Limited	ZOTA	₹813.35	₹22,291,971,460.00	₹43,805.00

Key Executives

Head of Corporate Quality Assurance & Regulatory Affairs

Dr. Prashant Baban Zate

Gender: Not Specified

Year Born:

President - Business Development, Strategy and R&D

Dr. Shekhar Bhaskar Bhirud

Gender: Not Specified

Year Born:

Technical Head

Dr. Shireesh Bhalchandra Ambhaikar

Gender: Not Specified

Year Born:

Chief Financial Officer

Mr. Krishna Raghunathan

Gender: male

Year Born:

Chief Scientific Officer

Dr. Sushanta Kumar Gouranga Mishra

Gender: Not Specified

Year Born:

Joint Managing Director

Ms. Shivani Satish Wagh

Gender: female

Year Born: 1991

Whole-time Director

Ms. Smita Satish Wagh

Gender: female

Year Born: 1958

Whole Time Director

Mr. Balasaheb Gulabrao Sawant

Gender: male

Year Born: 1964

Founder, Executive Chairman & Whole Time Director

Dr. Satish Waman Wagh

Gender: Not Specified

Year Born: 1955

Managing Director

Dr. Saloni Satish Wagh

Gender: Not Specified

Year Born: 1990

FAQs about Supriya Lifescience Limited

Who is the CEO of the company?

The CEO is Dr. Satish Waman Wagh.

What is the current market price of the stock?

The current price is ₹614.65.

What is the 52-week price range?

The range is ₹305.5-835.2.

What is the market capitalization of the company?

The market capitalization is ₹4,946.88 crores.

What is the dividend yield?

The dividend yield is 0.13%.

What is the Price-to-Earnings (P/E) ratio?

The P/E ratio is 28.31.

Which sector does the company belong to?

The company operates in the Healthcare sector.

What does the company do?

Overview of Supriya Lifescience Limited (ISIN: INE07RO01027) is a leading Biotechnology in India. With a market capitalization of ₹4,946.88 crores and an average daily volume of 302,031 shares, it operates in the Biotechnology. The company last declared a dividend of ₹0.8.

Supriya Lifescience Limited

Supriya Lifescience Limited Graph

Supriya Lifescience Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges

Overview of Supriya Lifescience Limited

Financial Ratios Every Investor Needs

Stock Dividend of SUPRIYA

Stock Rating Details for SUPRIYA

Annual Financial Income Report

Annual Financials Balance Sheet

Annual Financials Cash Flow Statement

Quarterly Financial Income Report

Quarterly Financials Balance Sheet

Quarterly Financials Cash Flow Statement

Splits History

Similar Stocks: Biotechnology

Key Executives

FAQs about Supriya Lifescience Limited

QUICK LINKS

STAY CONNECTED